Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.
In patients with COPD, lung methylation profiles differ according to the severity of airflow limitation and some epigenetic changes translate into specific gene expression changes in the lung.
When evaluating a patient with newly identified interstitial lung disease, using a questionnaire may help clinicians identify potentially relevant exposures for hypersensitivity pneumonitis.
The use of exhaled breath analysis via eNose technology can help accurately distinguish various subtypes of interstitial lung disease.
The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 INCREASE study.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
Researchers confirmed the feasibility of conducting a randomized, triple-blinded, sham-controlled trial of ambulatory oxygen delivered via portable oxygen concentrator to evaluate its effects in patients with interstitial lung disease.
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Hospitalized patients with COPD or interstitial lung disease are not frequently prescribed opioids for severe breathlessness, and those who are prescribed opioids for breathlessness do not receive timely follow-up.
A new genomic classifier added to bronchoscopic lung cryobiopsy increased the diagnostic confidence of physicians for interstitial lung disease.
